

## Zorginstituut Nederland

> Return address PO Box 320, 1110 AH Diemen

Minister of Medical Care and Sports  
Care of: GMT Management  
PO Box 20350  
2500 EJ THE HAGUE

2020024723

Date 11 June 2020  
Subject Trifarotene (50 microgram/gram cream) (Aklief®)

### National Health Care Institute

Care II  
Cardiovascular & Pulmonary

Willem Dudokhof 1  
1112 ZA Diemen  
PO Box 320  
1110 AH Diemen  
www.zorginstituutnederland.nl  
info@zinl.nl

T +31 (0)20 797 85 55

### Contact

Dr T.H.L. Tran  
T +31 (0)6-12001412

### Our reference

2020024723

Dear Mr van Rijn,

In your letter of 13 May 2020 (CIBG-20-0437), you asked Zorginstituut Nederland to assess whether the product trifarotene (Aklief®) can be included in the medicine reimbursement system (GVS). You have asked us to deal with this request by means of a marginal review. The considerations are included in the GVS report attached to this letter.

Trifarotene (Aklief®) is a retinoid, indicated for the cutaneous treatment of acne vulgaris on the face and/or torso in patients aged 12 years and over when a large amount of comedones, papules and pustules are present. Trifarotene (50 microgram/gram cream) is available as a bottle with an air-free pumping system with a content of 75 grams.

### Conclusion of the marginal review

Based on the criteria for interchangeability, it can be concluded that trifarotene (Aklief®) is interchangeable with the other medicinal products in the GVS cluster OD10ADADC V, which includes: tretinoin, adapalene and adapalene/benzoyl peroxide. The standard dose can be set to 1 gram.

### Advice

We advise you to include trifarotene (Aklief®) on List 1A in cluster OD10ADADC V of the GVS. 1 gram can be used as a standard dosage.

Yours sincerely,

Sjaak Wijma  
*Chair of the Executive Board*